USP20-mediated PGAM1 stabilization promotes glycolysis and confers osimertinib resistance in non-small cell lung carcinoma

Yunchong Meng Xiaojun Wang Shihao Wu Wei Lin Mingliang Wang Kuo Li Peiyuan Mei Quanfu Huang Yongde Liao Na Wang

Jul 2026 · Oncogene · Vol 45, pp. 3358 - 3372 · 0 citations · 49 references

Medicine

TL;DR

This study shows that elevated USP20 expression drives osimertinib resistance and is associated with poor clinical outcomes in osimertinib-resistant NSCLC, and identifies compound 89131-02-2 as a novel and selective inhibitor that targets the USP20 C154 catalytic site.

DOI PubMed Semantic Scholar

View source

Similar papers

Aug 2026

LINC00511 drives osimertinib resistance in LUAD via PERK kinase: A clinical biomarker with enzymatic therapeutic potential.

These findings provide clinical evidence for the early diagnosis and risk stratification of Osimertinib resistance, and suggest that targeting the LINC00511-PERK-Nrf2 axis may become a novel therapeutic strategy for restoring drug sensitivity.

Qingyang Lei, Jing Peng, Na Li et al. · Cellular Signalling · 0 citations

Open access Jul 2026

AARS1-catalyzed H4K12 lactylation promotes HCC resistance to targeted therapy by activating RAPGEF3-RAP1 signaling.

A novel metabolic-epigenetic mechanism whereby lactate modulates hepatocellular carcinoma sensitivity to targeted therapies through histone lactylation is delineated and suggests AARS1-H4K12la-RAPGEF3 axis may serve as an interventional target to overcome targeted drug resistance, offering a promising strategy to enhan...

Tanlun Zeng, Wanwan Zhu, Guanqun Sun et al. · Cell Death and Disease · 1 citation

Jul 2026

USP15-mediated deubiquitination of FIS1 impairs mitochondrial function and sensitizes bladder cancer cells to radiotherapy

USP15 plays a critical role in regulating radiosensitivity, and targeting USP15-mediated mitochondrial OXPHOS may represent a promising therapeutic strategy to enhance the efficacy of radiotherapy in bladder cancer, providing a novel treatment approach for the treatment of bladder cancer patients.

Ru-Xin Xiong, Ming-Xu Wang, Jiaming Du et al. · Oncogene · 0 citations

Aug 2026

Targeting EP2 overcomes osimertinib-tolerant persisters through metabolic and inflammatory reprogramming in non-small cell lung cancer.

Clinically, high expression levels of EP2, phosphorylated GYS1, and HIF-1α in tumor tissues correlated with poor therapeutic response to osimertinib, and elevated serum concentrations of inflammatory cytokines in NSCLC patients, suggesting that EP2 serves as a critical regulator linking metabolic reprogramming and infl...

Hai-Yang Yu, Ling Lu, Xue Hu et al. · International Immunopharmaco... · 0 citations

Open access Sep 2026

Targeting PGAM1 Y119 phosphorylation resensitizes non-small-cell lung cancer to cisplatin therapy by promoting oxidative stress and DNA damage

Findings reveal a novel mechanism by which PGAM1 Y119 phosphorylation drives chemoresistance and suggest that targeting this phosphorylation event represents a potential therapeutic strategy to overcome cisplatin resistance in NSCLC.

Wen-Xia Zhang, Yan-Zhao Qu, Xin Wang et al. · Journal of Biological Chemis... · 0 citations

Jul 2026

Abstract A062: Selective USP10 inhibition by GL-458 re-sensitizes platinum-resistant non-small cell lung cancer through DNA damage response disruption

Platinum-based chemotherapy remains one of the standard treatments for advanced non-small cell lung cancer (NSCLC); however, most patients eventually relapse because of acquired resistance. A major driver of therapeutic resistance is hyperactivation of the DNA damage response (DDR), which allows tumor cells to repair...

Sadaf Dorandish, Komal Bhayekar, Amirreza Samarbakhsh et al. · Clinical Cancer Research · 0 citations